GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » E10

Paratek Pharmaceuticals (FRA:N4CN) E10 : €-4.36 (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Paratek Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2023 was €-0.231. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-4.36 for the trailing ten years ended in Jun. 2023.

During the past 3 years, the average E10 Growth Rate was 4.10% per year. During the past 5 years, the average E10 Growth Rate was 13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Paratek Pharmaceuticals was 57.40% per year. The lowest was 4.10% per year. And the median was 32.10% per year.

As of today (2024-06-10), Paratek Pharmaceuticals's current stock price is €2.024. Paratek Pharmaceuticals's E10 for the quarter that ended in Jun. 2023 was €-4.36. Paratek Pharmaceuticals's Shiller PE Ratio of today is .


Paratek Pharmaceuticals E10 Historical Data

The historical data trend for Paratek Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals E10 Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.48 -5.97 -5.49 -5.70 -5.26

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.32 -5.66 -5.26 -4.71 -4.36

Competitive Comparison of Paratek Pharmaceuticals's E10

For the Biotechnology subindustry, Paratek Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Shiller PE Ratio falls into.



Paratek Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Paratek Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.231/128.7287*128.7287
=-0.231

Current CPI (Jun. 2023) = 128.7287.

Paratek Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201309 -2.244 98.790 -2.924
201312 -2.540 98.326 -3.325
201403 -1.301 99.695 -1.680
201406 -1.590 100.560 -2.035
201409 -4.004 100.428 -5.132
201412 -0.305 99.070 -0.396
201503 -0.684 99.621 -0.884
201506 -0.855 100.684 -1.093
201509 -1.185 100.392 -1.519
201512 -1.102 99.792 -1.422
201603 -1.598 100.470 -2.047
201606 -1.504 101.688 -1.904
201609 -0.927 101.861 -1.172
201612 -1.062 101.863 -1.342
201703 -1.066 102.862 -1.334
201706 -0.587 103.349 -0.731
201709 -0.646 104.136 -0.799
201712 -0.659 104.011 -0.816
201803 -0.738 105.290 -0.902
201806 -0.805 106.317 -0.975
201809 -0.866 106.507 -1.047
201812 -0.624 105.998 -0.758
201903 -0.974 107.251 -1.169
201906 -0.903 108.070 -1.076
201909 -0.908 108.329 -1.079
201912 -0.729 108.420 -0.866
202003 -0.597 108.902 -0.706
202006 -0.471 108.767 -0.557
202009 -0.391 109.815 -0.458
202012 -0.444 109.897 -0.520
202103 -0.328 111.754 -0.378
202106 0.166 114.631 0.186
202109 -0.315 115.734 -0.350
202112 -0.584 117.630 -0.639
202203 -0.318 121.301 -0.337
202206 -0.312 125.017 -0.321
202209 -0.384 125.227 -0.395
202212 -0.113 125.222 -0.116
202303 -0.327 127.348 -0.331
202306 -0.231 128.729 -0.231

Add all the adjusted EPS together and divide 10 will get our e10.


Paratek Pharmaceuticals  (FRA:N4CN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Paratek Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines